Intratumoral delivery of VLP‐encapsulated CpG‐A enables a specific antitumor response by selectively activating tumor‐associated pDCs and conventional DCs that present tumor antigens to CD8+ T cells,13 and culminates in antitumor CD8+ T‐cell activation with improved systemic antitumor activity.8, 14. This evidence concerns the gene CD8A and neoplasm.